Principia Biopharma files for Initial Public Offering in the US
Shots:
- Principia files IPO with $86mn having ticker PRNB
- Principia’s lead product PRN1008 (BTKi) with Ph III & II for pemphigus and immune thrombocytopenic purpura respectively
- In 2017- Principia collaborated with AbbVie for oral immunoproteasome inhibitors and with Sanofi for development of PRN2246 (BTKi
Ref: Principia Biopharma | Image: Pharmaletter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com